Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
Their findings could prove to be a breakthrough in not only treating tumors, but ensuring cancer doesn’t return years later — giving peace of mind to patients that their illness is truly gone.
“Not all cancer cells are the same, even in the same tumor,” said Dr. William Taylor, a professor in the Department of Biological Sciences in the UToledo College of Natural Sciences and Mathematics. “There is a lot of variability and some of the cells, like cancer stem cells, are much nastier. Everyone is trying to figure out how to kill them, and this may be one way to do it.”
Taylor and Dr. L.M. Viranga Tillekeratne, a professor in the Department of Medicinal and Biological Chemistry in the UToledo College of Pharmacy and Pharmaceutical Sciences, reported their findings in a paper recently published in the journal Scientific Reports.
Cancer stem cells are an intriguing target for researchers because of their potential to re-seed tumors.
When doctors remove a tumor surgically or target it with chemotherapy drugs or radiation therapy, the cancer may appear to be gone. However, evidence suggests that a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations.
Those cancer stem cells, Taylor said, are similar to dandelions in a well-manicured lawn.
“You could chop the plant off, but it will drop a seed. You know the seeds are there, but they’re hiding,” he said. “You pull one weed out and another comes up right after it. Cancers can be like this as well.”
The small molecule they have isolated appears to lock on to those stem cells and kill them by blocking their absorption of an amino acid called cystine.
UToledo was awarded a patent for the discovery late last year.
For Tillekeratne and Taylor, uncovering a new class of therapeutic molecules could prove to be an even larger contribution to cancer research than the project they initially envisioned.
“At present, there are no drugs that can kill cancer stem cells, but people are looking for them,” Tillekeratne said. “A lot of drugs are discovered by serendipity. Sometimes in research if you get unexpected results, you welcome that because it opens up a new line of research. This also shows the beauty of collaboration. I wouldn’t have been able to do this on my own, and [Taylor] wouldn’t have been able to do it on his own.”
Tillekeratne has received a three-year, $449,000 grant from the National Institutes of Health National Cancer Institute to continue testing the effectiveness of the newly identified therapy.
Because the molecules so selectively target cancer stem cells, it’s possible they could ultimately be paired with other chemotherapy drugs to deliver a more comprehensive treatment.
However, the researchers have found their agents show stand-alone promise in treating sarcomas and a subtype of breast cancer known as claudin-low breast cancer, which represents up to 14 percent of all breast cancers and can be particularly difficult to treat.
The Latest on: Cancer-killing agents
[google_news title=”” keyword=”cancer-killing agents” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer-killing agents
- We should leave animals out of our war on canceron February 21, 2024 at 6:18 am
As the nation reels from the shock of King Charles’ diagnosis — and millions of others across the UK go through their own battles with cancer — the pressure has never been higher for the government to ...
- Use of Erythropoietin-stimulating Agents in Breast Cancer Patients: A Risk Reviewon February 19, 2024 at 4:00 pm
Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related ...
- FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolveson February 14, 2024 at 4:15 pm
Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack ...
- A pill to tackle bowel canceron January 24, 2024 at 4:00 pm
It targets an enzyme that makes the tumour produce a cancer-killing agent, unlike infused therapy which visits other body sites in addition to the tumour. Recent trials involving 1,200 patients ...
- Gold Nanoparticles: Agents For Noninvasive Cancer Therapyon January 3, 2024 at 8:49 pm
Gold nanoparticles are potential and very practical agents in therapeutic applications. Researchers from the University of California, San Francisco and Georgia Institute of Technology, writing ...
- Cancer-Killing Compound From A Funguson December 22, 2023 at 4:27 am
A cancer-killing compound called rasfonin has been ... might have some tremendous potential as a prototype anticancer agent, but no one has been able to study or develop it because it's so hard ...
- Multivitamins highlighted as possible cancer agentson November 12, 2023 at 8:10 pm
Dr Mohammad Muneeb Khan, a National Health Service (NHS) oncologist from the United Kingdom and founder of the UK-based international charity, “Killing Cancer Kindly” (KCK), says that ...
- Cancer-killing pill that annihilates tumours hailed as 'holy grail' breakthroughon August 1, 2023 at 8:37 am
‘Our cancer-killing pill is like a snowstorm that closes ... pill made cancer cells more susceptible to chemical agents that cause DNA or chromosome damage, hinting that AOH1996 could become ...
- Scientists Develop a Cancer Vaccine to Simultaneously Kill and Prevent Brain Canceron January 29, 2023 at 3:59 pm
Cancer vaccines are an active area of research ... tool CRISPR-Cas9 and repurposed them to release tumor cell killing agents. In addition, the engineered tumor cells were designed to express ...
- Engineering a Dual-Action, Cancer Killing Vaccine (IMAGE)on January 4, 2023 at 11:05 am
Shah’s team engineered living tumor cells using the gene editing tool CRISPR-Cas9 and repurposed them to release tumor cell killing agent ... safety switch into the cancer cell, which, when ...
via Bing News